Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse model.
Mol Ther Methods Clin Dev
; 28: 284-299, 2023 Mar 09.
Article
in En
| MEDLINE
| ID: mdl-36816759